Dr Reddy’s inks pact with Gilead for Covid-19 drug

?OUR BUREAU Hyderabad | Updated on June 13, 2020 Published on June 13, 2020

Dr Reddy’s Laboratories Ltd

Dr. Reddy's Laboratories Ltd has entered into a non-exclusive Licensing Agreement with Gilead Sciences, Inc. (Gilead) on Remdesivir. 

As part of the agreement Gilead will grant Dr. Reddy’s the right to register, manufacture and sell Gilead’s investigational drug, Remdesivir, a potential treatment for Covid-19, in 127 countries including India.

Hyderabad -based Dr Reddy’s will receive technology transfer from Gilead for manufacturing of this drug. Dr. Reddy’s would need to do the manufacturing scale up and obtain regulatory approval for marketing of this drug in respective countries, according to a release. 

Remdesivir, an investigational antiviral therapy developed by Gilead, received Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration (USFDA) to treat Covid-19.


Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

Published on June 13, 2020
This article is closed for comments.
Please Email the Editor